RxDoctor Payments Data

Eugene Oliveto

Psychiatry · Bellevue, NENPI 1811061203

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.3% of the total across 138 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 28.0% of the total. Reporting peaked in 2022 at $706 and has fallen 62.8% since, to $263 in 2023.

$2,163in general payments, 2019–2025

Across 138 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$606
  • Otsuka America Pharmaceutical, Inc.$323
  • Takeda Pharmaceuticals U.S.A., Inc.$166
  • Lundbeck LLC$134
  • Novo Nordisk$115
  • Avanir Pharmaceuticals, Inc.$92
  • plus $728 from 22 others

What the payments were for

  • Food & beverage$2,12798%
  • Education$362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,163 in reported general payments places this provider in the 80th percentile of 160 psychiatry providers in Nebraska.

See all psychiatry providers in Nebraska

Other psychiatry in Bellevue

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →